{ "schemaVersion": 1, "organisationId": "O-5ce47dc997284609896f56b5cff3d792", "slug": "zoetis", "name": "Zoetis Inc.", "updatedAt": "2026-10-03T22:04:21.166674Z", "sections": [ { "type": "OVERVIEW", "text": "Zoetis Inc. is a global animal-health company that discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics and related services for companion animals and livestock. Its products serve dogs, cats, horses, cattle, swine, poultry, fish and sheep, across U.S. and international markets. [P38335893][P48191742]\n\nThe company’s stated purpose is “to nurture our world and humankind by advancing care for animals.” In 2025, Zoetis reported approximately $9.35 billion in revenue across its U.S. and International segments. It reports approximately 14,500 colleagues and products sold in more than 100 countries. [https://www.zoetis.com/our-company/our-story/about-us][P101835977][P48702618][https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance]\n[P38335893][P48191742][P101835977][P48702618][https://www.zoetis.com/our-company/our-story/about-us][https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance]", "updatedAt": "2026-10-03T22:04:21.166674Z" }, { "type": "PRODUCTS", "text": "Zoetis sells vaccines, medicines and parasite-control products for companion animals and livestock. Companion-animal products include Simparica Trio, a monthly chewable for dogs that protects against fleas, ticks, heartworm, roundworms and hookworms; Apoquel, a JAK1 inhibitor used for allergic itch and atopic dermatitis in dogs; and Cytopoint, an injection that reduces signs of canine atopic dermatitis. Its portfolio also includes Cerenia for vomiting and motion sickness, and the monthly injectable osteoarthritis-pain treatments Librela for dogs and Solensia for cats. [T11821245]\n\nLivestock products include Fostera and Suvaxyn vaccines for swine diseases, Poulvac vaccines for poultry diseases, and Rispoval and Bovi-Shield vaccines for cattle. Ceftiofur products are injectable broad-spectrum antibiotics; Draxxin is used to treat or prevent respiratory disease and other conditions in cattle and swine; and Dectomax is an injectable or pour-on treatment for internal and external parasites. Vaccine coverage and product use vary by formulation. [T3609540]\n\nZoetis’ Vetscan diagnostics range includes benchtop and handheld point-of-care instruments and consumables. Vetscan Imagyst combines image recognition, algorithms and cloud-based AI for clinic diagnostics, including dermatology, fecal and urine-sediment analysis; its AI Masses application helps identify potentially neoplastic cells. Vetscan OptiCell is a cartridge-based AI hematology analyzer for complete blood count analysis. [P70506691][https://www.zoetis.com/products-and-science/diagnostics]\n\nIn the six months ended June 30, 2026, companion-animal products generated $3.227 billion, about 68.2% of company revenue, and livestock products generated $1.451 billion, about 30.7%; these percentages are calculated from the reported category and total revenue figures. [T17102764] For full-year 2025, Simparica and Simparica Trio accounted for approximately 16% of revenue, Apoquel and Apoquel Chewable about 12%, the top five product lines about 42%, and the top ten about 57%. [P104502385]\n[T11821245][T3609540][P70506691][T17102764][P104502385][https://www.zoetis.com/products-and-science/diagnostics]", "updatedAt": "2026-10-03T22:04:21.166674Z" }, { "type": "GEOGRAPHY", "text": "Zoetis reports two operating segments, U.S. and International. In 2025, U.S. segment revenue was $5.097 billion and International segment revenue was $4.254 billion, approximately 53.8% and 44.9% of total revenue, respectively; the reported $9.467 billion total also includes $116 million from contract manufacturing and human health. The company separately reported that operations outside the U.S. accounted for 45% of 2025 revenue. [T11415508][P45299461] No country-level revenue breakdown was identified.\n\nZoetis directly markets in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries. [P15365651] Its manufacturing network spans the U.S., Brazil, Italy, Norway, Ireland, Australia, China, Belgium, New Zealand and Spain. [T6325825] The company had approximately 1,700 employees in global R&D at year-end 2025; R&D headquarters is in Kalamazoo, Michigan, with operations in the U.S. and in Australia, Belgium, Brazil, China, Germany, India, Norway, Spain, the U.K. and Vietnam. [P104210591]\n[T11415508][P45299461][P15365651][T6325825][P104210591]", "updatedAt": "2026-10-03T22:04:21.166674Z" }, { "type": "SEGMENTS", "text": "Zoetis reports two geographic operating segments: U.S. and International. Both serve companion-animal and livestock markets with diversified animal-health products; the company does not report these product or species categories as separate operating segments. In FY2025, U.S. segment revenue was $5.097 billion (approximately 54% of company revenue) and International revenue was $4.254 billion (approximately 45%). Client Supply Services and human-health products account for approximately the remaining 1%. [P1056774][P50763591][P101835977][P48702618][P10940061][T11518266]\n\nAs a separate view of its business mix, Zoetis attributes approximately 70% of FY2025 revenue to companion-animal products and 29% to livestock products. The companion-animal portfolio serves pet health and veterinary care; livestock products focus on predicting, preventing, detecting and treating disease in food-producing animals. [P8255599][P112082363][P2514280]\n[P1056774][P50763591][P101835977][P48702618][P10940061][T11518266][T11518266][P8255599][P112082363][P2514280]", "updatedAt": "2026-10-03T22:04:21.166674Z" }, { "type": "HISTORY", "text": "Zoetis traces its origins to Pfizer’s animal-health work: Pfizer researchers discovered Terramycin in 1950, the company formed an Animal Agriculture division in 1952, and it renamed the division Pfizer Animal Health in 1988. [https://www.zoetis.com/our-company/our-story/history] Pfizer’s animal-health business expanded through product launches and acquisitions, including SmithKline Beecham’s animal-health division in 1995 and Pharmacia in the 2000s. [https://www.zoetis.com/global-assets/private/zoetis_history_timeline_march-9-2015.pdf]\n\nPfizer announced plans to take the business public in 2012. Zoetis began trading on the New York Stock Exchange in February 2013 and became fully independent from Pfizer on June 24 that year. [https://investor.zoetis.com/news/news-details/2012/Zoetis-Files-IPO-Registration-Statement/default.aspx] [https://news.zoetis.com/press-releases/press-release-details/2013/Zoetis-Closes-Initial-Public-Offering/default.aspx] [https://investor.zoetis.com/news/news-details/2013/Zoetis-Becomes-Fully-Independent-With-Acceptance-of-Pfizer-Shares-Tendered-in-Exchange-Offer/default.aspx]\n\nAfter becoming independent, Zoetis introduced companion-animal products including Apoquel, approved by the FDA in 2013, and Simparica, approved in 2016. [https://investor.zoetis.com/news/news-details/2013/FDA-Approves-APOQUEL-oclacitinib-tablet-to-Control-Itch-and-Inflammation-in-Allergic-Dogs/default.aspx] [https://www.zoetis.com/news-and-insights/featured-stories/fda-approves-simparicatm-%28sarolaner%29-chewables] In 2018, it completed the acquisition of veterinary diagnostics provider Abaxis. [https://news.zoetis.com/press-releases/press-release-details/2018/Zoetis-Completes-Acquisition-of-Abaxis-a-Leading-Global-Provider-of-Veterinary-Point-of-Care-Diagnostic-Instruments/default.aspx] Kristin Peck succeeded Juan Ramón Alaix as CEO in January 2020, and Zoetis completed its acquisition of Australian animal-health company Jurox in September 2022. [https://investor.zoetis.com/news/news-details/2019/Zoetis-Names-Kristin-Peck-to-Succeed-Juan-Ramn-Alaix-as-CEO-on-January-1-2020/default.aspx] [https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-the-Completion-of-its-Acquisition-of-Jurox-a-Leading-Provider-of-Livestock-and-Companion-Animal-Products/default.aspx]\n[https://www.zoetis.com/our-company/our-story/history][https://www.zoetis.com/global-assets/private/zoetis_history_timeline_march-9-2015.pdf][https://investor.zoetis.com/news/news-details/2012/Zoetis-Files-IPO-Registration-Statement/default.aspx][https://news.zoetis.com/press-releases/press-release-details/2013/Zoetis-Closes-Initial-Public-Offering/default.aspx][https://investor.zoetis.com/news/news-details/2013/Zoetis-Becomes-Fully-Independent-With-Acceptance-of-Pfizer-Shares-Tendered-in-Exchange-Offer/default.aspx][https://investor.zoetis.com/news/news-details/2013/FDA-Approves-APOQUEL-oclacitinib-tablet-to-Control-Itch-and-Inflammation-in-Allergic-Dogs/default.aspx][https://www.zoetis.com/news-and-insights/featured-stories/fda-approves-simparicatm-%28sarolaner%29-chewables][https://news.zoetis.com/press-releases/press-release-details/2018/Zoetis-Completes-Acquisition-of-Abaxis-a-Leading-Global-Provider-of-Veterinary-Point-of-Care-Diagnostic-Instruments/default.aspx][https://investor.zoetis.com/news/news-details/2019/Zoetis-Names-Kristin-Peck-to-Succeed-Juan-Ramn-Alaix-as-CEO-on-January-1-2020/default.aspx][https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-the-Completion-of-its-Acquisition-of-Jurox-a-Leading-Provider-of-Livestock-and-Companion-Animal-Products/default.aspx]", "updatedAt": "2026-10-03T22:04:21.166674Z" } ], "sources": [ { "id": "P38335893", "href": "https://app.finbar.com/go?id=P38335893", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P48191742", "href": "https://app.finbar.com/go?id=P48191742", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "https://www.zoetis.com/our-company/our-story/about-us", "href": "https://www.zoetis.com/our-company/our-story/about-us", "label": "www.zoetis.com" }, { "id": "P101835977", "href": "https://app.finbar.com/go?id=P101835977", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P48702618", "href": "https://app.finbar.com/go?id=P48702618", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance", "href": "https://www.zoetis.com/our-company/our-story/zoetis-at-a-glance", "label": "www.zoetis.com" }, { "id": "T11821245", "href": "https://app.finbar.com/go?id=T11821245", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "T3609540", "href": "https://app.finbar.com/go?id=T3609540", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P70506691", "href": "https://app.finbar.com/go?id=P70506691", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "https://www.zoetis.com/products-and-science/diagnostics", "href": "https://www.zoetis.com/products-and-science/diagnostics", "label": "www.zoetis.com" }, { "id": "T17102764", "href": "https://app.finbar.com/go?id=T17102764", "label": "Zoetis Inc. — Full financial report (2026 Q 2)", "documentId": "D-d159e646cf624c019f928b2ea5790087" }, { "id": "P104502385", "href": "https://app.finbar.com/go?id=P104502385", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "T11415508", "href": "https://app.finbar.com/go?id=T11415508", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P45299461", "href": "https://app.finbar.com/go?id=P45299461", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P15365651", "href": "https://app.finbar.com/go?id=P15365651", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "T6325825", "href": "https://app.finbar.com/go?id=T6325825", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P104210591", "href": "https://app.finbar.com/go?id=P104210591", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P1056774", "href": "https://app.finbar.com/go?id=P1056774", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P50763591", "href": "https://app.finbar.com/go?id=P50763591", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P10940061", "href": "https://app.finbar.com/go?id=P10940061", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "T11518266", "href": "https://app.finbar.com/go?id=T11518266", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P8255599", "href": "https://app.finbar.com/go?id=P8255599", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P112082363", "href": "https://app.finbar.com/go?id=P112082363", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "P2514280", "href": "https://app.finbar.com/go?id=P2514280", "label": "Zoetis Inc. — Full financial report (2025 Y)", "documentId": "D-7fbe8e5ba9754539abb3930b2e6a0f6e" }, { "id": "https://www.zoetis.com/our-company/our-story/history", "href": "https://www.zoetis.com/our-company/our-story/history", "label": "www.zoetis.com" }, { "id": "https://www.zoetis.com/global-assets/private/zoetis_history_timeline_march-9-2015.pdf", "href": "https://www.zoetis.com/global-assets/private/zoetis_history_timeline_march-9-2015.pdf", "label": "www.zoetis.com" }, { "id": "https://investor.zoetis.com/news/news-details/2012/Zoetis-Files-IPO-Registration-Statement/default.aspx", "href": "https://investor.zoetis.com/news/news-details/2012/Zoetis-Files-IPO-Registration-Statement/default.aspx", "label": "investor.zoetis.com" }, { "id": "https://news.zoetis.com/press-releases/press-release-details/2013/Zoetis-Closes-Initial-Public-Offering/default.aspx", "href": "https://news.zoetis.com/press-releases/press-release-details/2013/Zoetis-Closes-Initial-Public-Offering/default.aspx", "label": "news.zoetis.com" }, { "id": "https://investor.zoetis.com/news/news-details/2013/Zoetis-Becomes-Fully-Independent-With-Acceptance-of-Pfizer-Shares-Tendered-in-Exchange-Offer/default.aspx", "href": "https://investor.zoetis.com/news/news-details/2013/Zoetis-Becomes-Fully-Independent-With-Acceptance-of-Pfizer-Shares-Tendered-in-Exchange-Offer/default.aspx", "label": "investor.zoetis.com" }, { "id": "https://investor.zoetis.com/news/news-details/2013/FDA-Approves-APOQUEL-oclacitinib-tablet-to-Control-Itch-and-Inflammation-in-Allergic-Dogs/default.aspx", "href": "https://investor.zoetis.com/news/news-details/2013/FDA-Approves-APOQUEL-oclacitinib-tablet-to-Control-Itch-and-Inflammation-in-Allergic-Dogs/default.aspx", "label": "investor.zoetis.com" }, { "id": "https://www.zoetis.com/news-and-insights/featured-stories/fda-approves-simparicatm-%28sarolaner%29-chewables", "href": "https://www.zoetis.com/news-and-insights/featured-stories/fda-approves-simparicatm-%28sarolaner%29-chewables", "label": "www.zoetis.com" }, { "id": "https://news.zoetis.com/press-releases/press-release-details/2018/Zoetis-Completes-Acquisition-of-Abaxis-a-Leading-Global-Provider-of-Veterinary-Point-of-Care-Diagnostic-Instruments/default.aspx", "href": "https://news.zoetis.com/press-releases/press-release-details/2018/Zoetis-Completes-Acquisition-of-Abaxis-a-Leading-Global-Provider-of-Veterinary-Point-of-Care-Diagnostic-Instruments/default.aspx", "label": "news.zoetis.com" }, { "id": "https://investor.zoetis.com/news/news-details/2019/Zoetis-Names-Kristin-Peck-to-Succeed-Juan-Ramn-Alaix-as-CEO-on-January-1-2020/default.aspx", "href": "https://investor.zoetis.com/news/news-details/2019/Zoetis-Names-Kristin-Peck-to-Succeed-Juan-Ramn-Alaix-as-CEO-on-January-1-2020/default.aspx", "label": "investor.zoetis.com" }, { "id": "https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-the-Completion-of-its-Acquisition-of-Jurox-a-Leading-Provider-of-Livestock-and-Companion-Animal-Products/default.aspx", "href": "https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-the-Completion-of-its-Acquisition-of-Jurox-a-Leading-Provider-of-Livestock-and-Companion-Animal-Products/default.aspx", "label": "news.zoetis.com" } ] }